Polish Journal of Paediatrics
en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2025
vol. 100
 
Share:
Share:
Review paper

Juvenile-onset recurrent respiratory papillomatosis

Anna Karwowska
1
,
Aleksandra Wojno
1
,
Karolina Dorobisz
1

  1. Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wrocław, Poland
Pediatr Pol 2025; 100 (2): 173-176
Online publish date: 2025/06/01
Article file
Get citation
 
PlumX metrics:
 
1. Bertino G, Pedretti F, Mauramati S, et al. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. Acta Otorhinolaryngol Ital 2023; 43: S111-22.
2. Lawlor C, Balakrishnan K, Bottero S, et al. International Pediatric Otolaryngology Group (IPOG): juvenile-onset recurrent respiratory papillomatosis consensus recommendations. Int J Pediatr Otorhinolaryngol 2020; 128: 109697.
3. Lepine C, Leboulanger N, Badoual C. Juvenile onset recurrent respiratory papillomatosis: what do we know in 2024 ? Tumour Virus Res 2024; 17: 200281.
4. Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: a 2020 perspective. Laryngoscope Investig Otolaryngol 2021; 6: 340-345.
5. Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF. Systemic bevacizumab (avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021; 131: 1138-1146.
6. Li SL, Wang W, Zhao J, Zhang FZ, Zhang J, Ni X. A review of the risk factors associated with juvenile-onset recurrent respiratory papillomatosis: genetic, immune and clinical aspects. World J Pediatr 2022; 18: 75-82.
7. Amiling R, Meites E, Querec TD, et al. Juvenile-onset recurrent respiratory papillomatosis in the United States, epidemiology and HPV types-2015-2020. J Pediatric Infect Dis Soc 2021; 10: 774-781.
8. Wolf J, Kist LF, Pereira SB, et al. Human papillomavirus infection: epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol 2024; 34: e2537.
9. Nantel É, Mayrand MH, Audibert F, et al. Association between the mode of delivery and vertical transmission of human papillomavirus. Viruses 2024; 16: 303.
10. Kurita T, Chitose S, Sato K, et al. Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics. Laryngoscope Investig Otolaryngol 2019; 4: 89-94.
11. Lépine C, Voron T, Berrebi D, et al. Juvenile-onset recurrent respiratory papillomatosis aggressiveness: in situ study of the level of transcription of HPV E6 and E7. Cancers (Basel) 2020; 12: 1-12.
12. Conrady MC, Suarez I, Gogl G, et al. Structure of high-risk papillomavirus 31 E6 oncogenic protein and characterization of E6/E6AP/p53 complex formation. J Virol 2020; 95: e00730-20.
13. Chen L, Hu H, Pan Y, et al. The role of HPV11 E7 in modulating STING-dependent interferon β response in recurrent respiratory papillomatosis. J Virol 2024; 98: e0192523.
14. Khreefa Z, Isaac V, Poulik J, et al. Correlation between E6 and E7 oncogenes and malignant transformation of laryngeal papillomatosis (LP) with human papillomavirus (HPV) in pediatric population. Fetal Pediatr Pathol 2021; 40: 290-294.
15. Sarafoleanu C, Lapicus G, Lupu AI, Budu V. Difficulties in the treatment of recurrent juvenile laryngeal papillomatosis associated with pemphigus vulgaris. Romanian J Rhinol 2020; 10: 38-44.
16. Wang W, Xi Y, Li S, et al. Restricted recruitment of NK cells with impaired function is caused by hpv-driven immunosuppressive microenvironment of papillomas in aggressive juvenile-onset recurrent respiratory papillomatosis patients. J Virol 2022; 96.
17. Coordes A, Grund D, Mainka A, et al. [Recurrent laryngeal papillomatosis]. HNO 2023; 71: 77-82.
18. Mudd P, Wikner E, Rana MS, Zalzal G. Presenting symptom as a predictor of clinical course in juvenile onset recurrent respiratory papillomatosis. Laryngoscope 2021; 131: 1670-1675.
19. Labedz G, Scatolini ML, Ruvinsky S, Rodriguez HA. Factors related to extralaryngeal spread in juvenile recurrent respiratory papillomatosis. Laryngoscope 2021; 131: 1652-1656.
20. Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report. Int J Pediatr Otorhinolaryngol 2020; 128: 109706.
21. Bedard MC, de Alarcon A, Kou YF, et al. HPV strain predicts severity of juvenile-onset recurrent respiratory papillomatosis with implications for disease screening. Cancers (Basel) 2021; 13: 2556.
22. Yang Q, Li Y, Ma L, et al. Long-term outcomes of juvenile onset recurrent respiratory papillomatosis with pulmonary involvement. Laryngoscope 2021; 131: EE2277-E2283.
23. Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review. Pediatric Health Med Ther 2020; 11: 39.
24. Alves Melo IM, Pereira Viana MR, Pupin B, Bhattacharjee TT, de Azevedo Canevari R. PCR-RFLP and FTIR-based detection of high-risk human papilloma virus for cervical cancer screening and prevention. Biochem Biophys Rep 2021; 26: 100993.
25. Williams J, Kostiuk M, Biron VL. Molecular detection methods in HPV-related cancers. Front Oncol 2022; 12: 864820.
26. Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018; 3: 22-34.
27. Xiao Y, Zhang X, Ma L, Wang J. Long-term outcomes of juvenile-onset recurrent respiratory papillomatosis. Clin Otolaryngol 2021; 46: 161-167.
28. Rashid M, Saleem H, Karim MN, Najam A, Abdullah A, Haneef J. Role Of CO2 laser & microdebrider in the treatment of juvenile onset recurrent respiratory papillomatosi. J Pak Med Assoc 2023; 73: 1370-1373.
29. Zeleník K, Komínek P, Staníková L, Formánek M. Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas. Laryngoscope 2021; 131: E518-520.
30. Enrique OH, Eloy SH, Adrian TP, Perla V. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: a series of three pediatric cases and literature review. Am J Otolaryngol 2021; 42: 103126.
31. Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 2013; 139: 496-501.
32. Wang Y, Dai PD, Zhang TY. Experimental research on the therapeutic effect of MMR vaccine to juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2019; 276: 801-803.
33. Schindele A, Al-Sabtti S, Olofsson K. Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden. Acta Otolaryngol 2024; 144: 71-75.
34. Meites E, Stone L, Amiling R, et al. Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States. Clin Infect Dis 2021; 73: 885-890.
35. Goon P, Sauzet O, Schuermann M, et al. Recurrent respiratory papillomatosis (RRP)-meta-analyses on the use of the HPV vaccine as adjuvant therapy. NPJ Vaccines 2023; 8: 49.
36. Balai E, Dronkers EAC, Al Yaghchi C, Gujral D, Sandhu G, Iacovidou A. Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults. J Laryngol Otol 2024; 138: 1133-1143.
37. Ponduri A, Azmy MC, Axler E, et al. The efficacy of human papillomavirus vaccination as an adjuvant therapy in recurrent respiratory papillomatosis. Laryngoscope 2023; 133: 2046-2054.
38. Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis 2019; 219: 1016-1425.
Copyright: © 2025 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.